Quick Answer
DNA X, Inc. reported Total Revenue of $58.30 million for the year ending 2024.
- DNA X, Inc. showed an increase of +14.5% in Total Revenue from 2024 to 2024.
- This data is from DNA X, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2018 to 2024 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $18.19 million | Q2 2018: $31.45 million | Q3 2018: $39.50 million | Q1 2019: $26.48 million | Q1 2019: $26.48 million | Q2 2019: $43.75 million | Q2 2019: $43.75 million | Q3 2019: $28.85 million | Q3 2019: $28.85 million | Q1 2020: $12.71 million | Q2 2020: $21.06 million | Q3 2020: $14.39 million | Q1 2021: $12.24 million | Q2 2021: $11.95 million | Q3 2021: $14.45 million | Q1 2022: $13.26 million | Q2 2022: $11.96 million | Q3 2022: $20.50 million | Q1 2023: $25.80 million | Q2 2023: $26.84 million | Q3 2023: $27.57 million | Q3 2023: $27.57 million | Q1 2024: $9.12 million | Q1 2024: $16.78 million | Q2 2024: $11.52 million | Q2 2024: $11.52 million | Q3 2024: $15.02 million | Q3 2024: $15.02 million | Q1 2025: $16.72 million | Q1 2025: $16.72 million | Q2 2025: $11.19 million | Q2 2025: $11.19 million | Q3 2025: $16.21 million | Q3 2025: $16.21 million.
- Over the full 9 years of available data (2018 to 2024), DNA X, Inc.'s Total Revenue has declined by 57.0%.
- Historical annual values: Fiscal year 2024: $58.30 million | Fiscal year 2024: $50.92 million | Fiscal year 2023: $93.63 million | Fiscal year 2023: $93.63 million | Fiscal year 2022: $69.83 million | Fiscal year 2021: $54.57 million | Fiscal year 2020: $63.99 million | Fiscal year 2019: $116.25 million | Fiscal year 2018: $135.67 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: